M&A / Deals Roche looks to Astex in $515m breast cancer deal PharmaphorumRoche's Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer.OncologyRead full story pharminent July 6, 2026 (Last updated: July 7, 2026) Pharmaphorum Roche’s Genentech unit has forged an alliance with Astex, worth up to $515m, to partner on a fragment-based drug discovery programme in breast cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Wegovy pill launches in UK as first daily oral GLP1 for weight managementNext: Novartis to acquire Myricx Bio in up to $1.5bn deal Related Stories M&A / Deals Argenx signs agreement to buy Forte Biosciences for $2.2bn pharminent July 28, 2026 M&A / Deals Argenx deepens immuno expertise with $2.2B Forte Biosciences buy pharminent July 27, 2026 M&A / Deals Repligen builds in cell therapy with $1.5bn BioLife takeover pharminent July 22, 2026
